Moderna (MRNA) Expected to Release Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) will likely be releasing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Moderna to announce earnings of ($1.10) per share and revenue of $890.25 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Moderna Stock Up 3.4%

MRNA opened at $228.44 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company’s 50-day moving average is $185.79 and its 200 day moving average is $88.36. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $254.48. The firm has a market capitalization of $91.20 billion, a P/E ratio of -28.59 and a beta of 1.16.

Analyst Upgrades and Downgrades

MRNA has been the subject of several analyst reports. Barclays increased their price objective on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research note on Monday, August 24th. Loop Capital set a $135.00 target price on Moderna in a research note on Wednesday, August 19th. CLSA raised Moderna to an “outperform” rating in a report on Friday, August 28th. William Blair downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. Finally, Bank of America lifted their price target on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $107.10.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s personalized cancer vaccine intismeran, used with Keytruda, reduced the risk of death or melanoma recurrence by 42% in a late-stage trial. The results bolster the candidate’s potential, though success in additional cancers and eventual commercial impact are not assured. Article: Moderna’s Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
• Neutral Sentiment: Moderna is scheduled to report third-quarter results on Nov. 6. Analysts expect sales of about $888.8 million and a loss of $1.37 per share, making the report a near-term catalyst for investors. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
• Negative Sentiment: Recent coverage warns that the stock’s steep rally and premium valuation could leave it vulnerable if earnings or vaccine-development news disappoints. One article also flags an obstacle to the cancer vaccine’s success, though the supplied article summary does not specify what it is. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
• Neutral Sentiment: Prediction markets have begun trading on FDA approval timing for the melanoma vaccine, raising questions about potential information leakage and insider trading. This adds regulatory and market scrutiny but does not itself indicate an FDA decision. Article: What Is Moderna Answering As FDA Vaccine Betting Markets Grow?

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 39,145 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the sale, the president owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock valued at $33,875,904 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.